From July 1, 2023 to October 9, 2023, the company has repurchased 30,000 shares, representing 0.005243% for CNY 0.49 million. With this, the company has completed the repurchase of 9,865,793 shares, representing 1.7% for CNY 200 million under the buyback announced on October 21, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.64 CNY | +1.85% |
|
+2.74% | -9.77% |
12/06 | Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification | MT |
26/04 | Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.77% | 1.36B | |
-6.61% | 12.07B | |
+91.75% | 8.2B | |
-18.38% | 6.59B | |
+9.13% | 5.89B | |
-21.66% | 3.47B | |
+5.36% | 2.52B | |
+41.12% | 2.48B | |
+17.72% | 2.3B | |
-18.43% | 1.58B |
- Stock Market
- Equities
- 688289 Stock
- News Sansure Biotech Inc.
- Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.